<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02838069</url>
  </required_header>
  <id_info>
    <org_study_id>UF 9494</org_study_id>
    <nct_id>NCT02838069</nct_id>
  </id_info>
  <brief_title>A Study Evaluating the Efficacy of a Single Injection Autologous Adipose Derived Mesenchymal Stromal Cells in Patients With Knee Osteoarthritis</brief_title>
  <acronym>ADIPOA-2</acronym>
  <official_title>A Phase IIb, Prospective, Multicentre, Double-blind, Triple-arm, Randomized Versus Placebo Trial, to Assess the Efficacy of a Single Injection of Either 2 or 10 x 106 Autologous Adipose Derived Mesenchymal Stromal Cells (ASC) in the Treatment of Mild to Moderate Osteoarthritis (OA) of the Knee, Active and Unresponsive to Conservative Therapy for at Least 12 Months</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital, Toulouse</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>NATIONAL UNIVERSITY OF IRELAND, GALWAY (NUIG)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>ISTITUTO ORTOPEDICO RIZZOLI (IOR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>ETABLISSEMENT FRANCAIS DU SANG (EFS)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>ECRIN EUROPEAN CLINICAL RESEARCH INFRASTRUCTURE NETWORK (ECRIN)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>HUMAN MED AG (HM)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>STICHTING KATHOLIEKE UNIVERSITEIT (RUMC)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>SPORTS SURGERY CLINIC LIMITED</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>UNIVERSITA DEGLI STUDI DI PADOVA (UNIPD)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>EVANGELISCHES WALDKRANKENHAUS SPANDAU KRANKENHAUSBETRIEBS GGMBH (EWK)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>PINTAIL LTD (PT)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre National de la Recherche Scientifique, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>UNIVERSITAET ULM (UULM)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cambridge University Hospitals NHS Foundation Trust (CAM)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Aries srl (ARIES)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      ASCs will be administered via intra-articular use into the knee joint affected by OA where
      they are expected to exert their therapeutic effects.

      The objective of this clinical trial is to generate efficacy and tolerability profiles of
      single injections of 2 dosages of autologous ASCs versus standard of care (placebo), when
      administered locally into a knee joint affected by OA after in vitro cell expansion. The
      potential of ASC to lead to a disease-modifying therapeutic option for the treatment of this
      chronic and debilitating disease will be assessed by MRI after 1 and 2 years.

      This will be a phase IIb, multi-centre, prospective, randomized, double-blind study,
      comparing culture-expanded autologous ASC with placebo.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement of pain or physical function</measure>
    <time_frame>Month 6</time_frame>
    <description>evaluate the efficacy of ASC in mild to moderate knee OA (KL 2-3) based on increase in the number of &quot;strict&quot; responders defined by improvements from baseline in WOMAC pain or physical function subscores 50% with absolute changes 20 mm at 6 month, compared to placebo</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disability</measure>
    <time_frame>Months 1, 3, 6, 12 and 24</time_frame>
    <description>assessed by WOMAC questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disability</measure>
    <time_frame>Months 1, 3, 6, 12 and 24</time_frame>
    <description>assessed by KOOS (Knee injury and Osteoarthritis Outcome Score questionnaire)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disability</measure>
    <time_frame>Months 1, 3, 6, 12 and 24</time_frame>
    <description>assessed by SAS questionnaire (The Short Arthritis Assessment Scale)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>Months 1, 3, 6, 12 and 24</time_frame>
    <description>assessed by SF-36 questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>painkillers consumption</measure>
    <time_frame>Months 1, 3, 6, 12 and 24</time_frame>
    <description>Changes from baseline (Day 0) to months 1, 3, 6, 12 and 24 in use of painkillers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Structural changes</measure>
    <time_frame>Months 12 and 24</time_frame>
    <description>Changes from baseline (Day 0) to months 12 and 24 in femorotibial joint space of the index knee on X-ray</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Structural changes</measure>
    <time_frame>Months 12 and 24</time_frame>
    <description>Changes from baseline (Day 0) to months 12 and 24 by MOAKS (MRI Osteoarthritis Knee score)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">153</enrollment>
  <condition>Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>2x106 ASC intra-articular injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Injection of Autologous adipose derived stem cells (2x106 ASC/5ml). The patient of this group will receive one single administration of the cells and will be followed for 12 months. A final follow up visit will occur at Month 24.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>10x106 ASC intra-articular injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Injection of Autologous adipose derived stem cells (10x106 ASC/5ml). The patient of this group will receive one single administration of the cells and will be followed for 12 months. A final follow up visit will occur at Month 24.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>0.5% glucose in saline with 4.5% albumin</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Injection (2x106 ASC/5ml).</intervention_name>
    <description>Injection of Autologous adipose derived stem cells (2x106 ASC/5ml). The patient of this group will receive one single administration of the cells and will be followed for 12 months. A final follow up visit will occur at Month 24.</description>
    <arm_group_label>2x106 ASC intra-articular injection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Injection (10x106 ASC/5ml).</intervention_name>
    <description>Injection of Autologous adipose derived stem cells (10x106 ASC/5ml). The patient of this group will receive one single administration of the cells and will be followed for 12 months. A final follow up visit will occur at Month 24.</description>
    <arm_group_label>10x106 ASC intra-articular injection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Injection of placebo 0.5% glucose in saline with 4.5% alb/5ml The patient of this group will receive one single administration and will be followed for 12 months. A final follow up visit will occur at Month 24.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Symptomatic mild to moderate osteoarthritis (OA) of the index knee as defined by the
             American college of Rheumatology (ACR)

          -  Must meet pain criteria at the time of screening/baseline visit since at least half of
             the days in the previous month

          -  NSAID washout of at least 2 days before screening/baseline

        Exclusion Criteria:

          -  Previous treatments acting on cartilage or bone metabolism

          -  Received intra-articular injection of corticosteroids, platelet rich plasma or
             hyaluronic acid within the previous 6 months,

          -  Significant trauma or surgery to the index knee within the last year or arthroscopy of
             the index knee within 12 months of screening.

          -  Kellgren-Lawrence Grade 1 or 4 in the index knee on any incidences.

          -  Osteoarthritis causing significant pain in any joint other than the identified knee,
             i.e., pain in hip, or contralateral knee (≥ 20 mm pain) as confirmed by a separate VAS
             at baseline for any other painful joint concerned

          -  History of joint replacement of the knee or hip within the previous 12 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christian Jorgensen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Montpellier</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christian Jorgensen, MD, PhD</last_name>
    <phone>+33467337796</phone>
    <email>christian.jorgensen@inserm.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yves-Marie Pers, MD</last_name>
    <phone>+33467337231</phone>
    <email>ym-pers@chu-montpellier.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UH Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Jorgensen, MD</last_name>
      <phone>0033 467 337798</phone>
      <email>christian.jorgensen@chu-montpellier.fr</email>
    </contact>
    <contact_backup>
      <last_name>Yves Marie PERS, MD</last_name>
      <email>rosanna.ferreira@chu-montpellier.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Christian Jorgensen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 13, 2016</study_first_submitted>
  <study_first_submitted_qc>July 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 20, 2016</study_first_posted>
  <last_update_submitted>November 7, 2016</last_update_submitted>
  <last_update_submitted_qc>November 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

